CIK 0001160308
- Non-accelerated filer
- Smaller reporting company
Savara Inc
Sign in to watch- Ticker
- SVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841318182
- Phone
- +51 285113796
- Business address
- 6836 BEE CAVE ROAD, BUILDING 3, SUITE 201, AUSTIN, TX, 78746
- Former names
- Mast Therapeutics, Inc., ADVENTRX PHARMACEUTICALS INC, BIOKEYS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-05 | Lowrance David L Chief Financial Officer | Exercise or conversion | +320 | $1.51 | $483 | 320 |
| 2019-04-05 | Lowrance David L Chief Financial Officer | Sale | −320 | $9.00 | $3K | 0 |
| 2019-04-05 | Lowrance David L Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −320 | 92,918 | ||
| 2019-04-05 | Jouhikainen Jaakko Taneli President and COO | Sale | −849 | $9.00 | $8K | 183,905 |
| 2019-04-04 | Lowrance David L Chief Financial Officer | Exercise or conversion | +2,446 | $1.51 | $4K | 2,446 |
| 2019-04-04 | Lowrance David L Chief Financial Officer | Sale | −2,446 | $9.00 | $22K | 0 |
| 2019-04-04 | Lowrance David L Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,446 | 93,238 | ||
| 2019-04-04 | Jouhikainen Jaakko Taneli President and COO | Sale | −7,815 | $9.00 | $70K | 184,754 |
| 2019-02-04 | Elam Nevan C Director | Exercise or conversion | +21,682 | $0.19 | $4K | 21,682 |
| 2019-02-04 | Elam Nevan C Director | Exercise or conversion · Stock Option (Right to Buy) | −21,682 | 0 | ||
| 2018-12-21 | Neville Robert N Chief Executive Officer | Purchase | +23,517 | $6.38 | $150K | 498,028 |
| 2018-12-13 | Elam Nevan C Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-12-13 | Pauls Matthew Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-12-13 | RAMSAY DAVID A Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-12-13 | PIKOVER YURI Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-12-13 | McCracken Joseph S Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-12-13 | Hawkins Richard J Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2018-11-01 | Lowrance David L Chief Financial Officer | Sale | −18,480 | $9.22 | $170K | 0 |
| 2018-08-02 | Jouhikainen Jaakko Taneli | Grant or award · Stock Option (Right to Buy) | +375,000 | 375,000 | ||
| 2018-08-02 | Neville Robert N Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 |
Page 17 of 20 · 390 trades